Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Discovery & Development

Discovery & Development Contract Development Services

Trials of a Medicine Maker

What is the current state of pharma contract development and manufacturing?

Discovery & Development Analytical Science

Pure and Simple(r)

| Stephanie Sutton

Making cancer drugs cheaper and more effective – with a paper “coffee” filter.

Discovery & Development Contract Development Services

A Nice Outsourcing View

| Stephanie Sutton

What is the current state of pharma contract development and manufacturing?

Discovery & Development Clinical Trials

Coping With the Complex Clinical Trial Landscape…

| James Strachan

Valarie Higgins discusses how clinical trials have evolved over the years and the key lessons she has learned while building her career in the industry.

Discovery & Development Bioprocessing - Upstream & Downstream

Boosting mAb Manufacture

| David Westman

mAbs are an important growth area for the biopharma industry – so we need more effective purification technologies.

Discovery & Development Drug Delivery

The Argument for Albumin

| Phil Morton

Products are becoming increasingly complex and we need to get better at recognizing the strategies with the best advantages.

Discovery & Development Drug Delivery

ADCs Assemble

| Charlie Johnson

Antibody drug conjugates have not yet lived up to their potential, but there is hope – if we turn to the right solutions and techniques.

Discovery & Development Analytical Science

Putting Peptides on the Map

Streamlined workflows help scientists plot a course for painless peptide mapping

Discovery & Development Biosimilars

What Regulators Want

| Bruno Speder

The path to market for a biosimilar involves an abbreviated approval process, focused on proving “biosimilarity”.

Discovery & Development Biosimilars

I’m a (Biosimilars) Believer!

| Stephanie Sutton

Why does the full potential of biosimilars remain untapped? Four experts weigh in.

Newsletter

Send me the latest from The Medicine Maker.

Sign up now

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register